Circadian Rhythms in the Pharmacokinetics and Clinical Effects of Beta-agonist, Theophylline, and Anticholinergic Medications in the Treatment of Nocturnal Asthma

References

• Arvidsson P, Larsson S, Lofdahl C G, et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168–73
   PubMed Web of Science ®Google Scholar
• Ball D I, Brittain R T, Coleman R A, et al. Salmeterol, a novel, long-acting beta2-adrenergic agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 1991; 104: 665–71
   PubMed Web of Science ®Google Scholar
• Barnes P J, Fitzgerald G A, Dollery C T. Orcadian variation in adrenergic response in asthmatic subjects. Clin Sci 1982; 62: 349–54
   Web of Science ®Google Scholar
• Barnes P J, Pauwels R A. Theophylline in the management of asthma: time for reappraisal. Eur Respir J 1994; 7: 579–91
   PubMed Web of Science ®Google Scholar
• Bogin R M, Ballard R D. Treatment of nocturnal asthma with pulse-release albuterol. Chest 1992; 102: 362–66
   PubMed Web of Science ®Google Scholar
• Bollinger A M, Young K YL, Gambertoglio J G, et al. Influence of food on the absorption of albuterol Rapatabs. J Allergy Clin Immunol 1989; 83: 123–26
   PubMedGoogle Scholar
• Brambilla C, Chastang C, Georges D, et al. Salmeterol compared with slow-release terbutaline in nocturnal asthma. Allergy 1994; 49: 421–26
   PubMed Web of Science ®Google Scholar
• Britton M G, Earnshaw J S, Palmer J BD. A 12 month comparison of salmeterol and salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062–67
   PubMed Web of Science ®Google Scholar
• Brown A, Smolensky M, ĎAlonzo G, et al. Circadian chronesthesy of the airways of healthy adults to the (J-agonist bronchodilator isoproterenol. Annu Rev Chrono-pharmocol 1988; 5: 163–66
   Google Scholar
• Catterall J L, Rhind G B, Whyte K F, et al. Is nocturnal asthma caused by changes in airway cholinergic activity. Thorax 1988; 43: 720–24
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera M G, Liccardi G. Effect of telenzepine, an Mi-selective muscarinic receptor antagonist, in patients with nocturnal asthma. Pulm Pharmacol 1994; 7: 91–97
   PubMedGoogle Scholar
• Coe C I, Barnes P J. Reduction of nocturnal asthma by an inhaled anticholinergic drug. Chest 1986; 90: 485–88
   PubMed Web of Science ®Google Scholar
• Cox I D, Hughes D TD, McConnell K. Ipratropium bromide in patients with nocturnal asthma. Postgrad Med J 1984; 60: 526–28
   PubMed Web of Science ®Google Scholar
• Creemers J D. A multicenter comparative study of salbuterol controlled release (Volmax) and sustained-release theophyllin (Theo-Dur) in the control of nocturnal asthma [abstract]. Eur Respir J 1988; 1(suppl 2)333s
   Google Scholar
• ĎAlonzo G E, Natim R A, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271: 1412–16
   PubMedGoogle Scholar
• ĎAlonzo G E, Smolensky M H, Feldman S, et al. Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning versus evening administration. Chest 1989; 107: 406–12
   Google Scholar
• ĎAlonzo G E, Smolensky M H, Feldman S, et al. Twenty-four hour lung function in adult patients with asthma: chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am Rev Respir Dis 1990; 142: 84–90
   PubMedGoogle Scholar
• Dorow P, Steinijans V W. Therapeutic advantage of unequal dosing of theophylline in patients with nocturnal asthma. Chronobiol Int 1987; 4: 349–57
   PubMed Web of Science ®Google Scholar
• Eriksson L, Jonson B, Eklundh G, et al. Nocturnal asthma: effects of slow-release terbutaline on spirometry and arterial blood gases. Eur Respir J 1988; 1: 302–5
   PubMedGoogle Scholar
• Eriksson N E, Haglind K, Ljungholm K. A comparison of sustained-release terbutaline and ordinary terbutaline in bronchial asthma. Br J Dis Chest 1982; 76: 202–4
   PubMedGoogle Scholar
• Faurschou P, Engel A M, Haanaes O C. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 1994; 49: 827–32
   PubMedGoogle Scholar
• Fitzgerald G A, Barnes P, Brown M N, . The circadian variability of circulating adrenaline and bronchomotor reactivity in asthma. Recent advances in chronobiology of allergy and immunology, M H Smolensky, A Reinberg, G Labrecque, et al. Pergamon, Oxford 1980; 89–94
   Google Scholar
• Fitzpatrick M F, Mackay T, Driver H, et al. Salmeterol in nocturnal asthma: a double-blind, placebo controlled trial of a long acting inhaled P2 agonist. Br Med J 1990; 301: 1365–68
   PubMedGoogle Scholar
• Gaultier C, Reinberg A, Girard F. Circadian changes in lung resistance and dynamic compliance in healthy and asthmatic children. Effects of two bronchodila-tors. Resp Physiol 1975; 31: 169–82
   Google Scholar
• Gaultier C, Reinberg A, Motohashi Y. Circadian rhythm in total pulmonary resistance of asthmatic children. Effects of a β-agonist agent. Chronobiol Int 1988; 5: 285–90
   PubMed Web of Science ®Google Scholar
• Grossman J, Morris R J, White K D, et al. Improved stability in oral delivery of albuterol provides less variability in bronchodilation in adults with asthma. Ann Allergy 1991; 66: 324–27
   PubMedGoogle Scholar
• Gunn S D, Ayres J G, McConchie S M. Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group. Eur J Clin Pharmacol 1995; 48: 23–28
   PubMedGoogle Scholar
• Harter J G, Reddy W IJ, Thorn G W. Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 1963; 296: 591–95
   Google Scholar
• Helms S. Diurnal stabilization of asthma with once daily evening administration of controlled release theophylline. Immunol Allergy Pract 1987; 9: 414–19
   Google Scholar
• Higenbottam M A, Khan A, Williams D O, et al. Controlled release salbutamol tablets versus aminophylline in the control of reversible airways obstruction. J Int Med Res 1989; 17: 435–41
   PubMedGoogle Scholar
• Temporal control of drug delivery, W JM Hrushesky, R Langer, F Theeuwes. Ann NY Acad Sci. 1991; 618
   Google Scholar
• Hussey E K, Donn K H, Powell J R. Albuterol extended-release products: a comparison of steady-state pharmacokinetics. Pharmacotherapy 1991; 11: 131–35
   PubMed Web of Science ®Google Scholar
• Joad J P, Ahrens R C, Lindgren S D, et al. Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. J Allergy Clin Immunol 1987; 79: 78–85
   PubMedGoogle Scholar
• Johnson M. The preclinical pharmacology of salmeterol: bronchodilator effects. Eur Respir Rev 1991; 1: 253–56
   Google Scholar
• Kemp J P, Bierman C W, Cocchetto D M. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Ann Allergy 1993; 70: 316–22
   PubMedGoogle Scholar
• Kesten S, Chapman K R, Broder I, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992; 69: 415–20
   PubMedGoogle Scholar
• Kidney J C, Dominguez M, Rose M, et al. Withdrawing chronic theophylline treatment increases airway lymphocytes in asthma. Thorax 1994; 49: 396
   Google Scholar
• Koeter G H, Postma D S, Keyzer J J, et al. Effect of oral slow-release terbutaline on early morning dyspnea. Eur J Clin Pharmacol 1985; 28: 159–62
   PubMed Web of Science ®Google Scholar
• Kraft M, Torvik J A, Trudeau J, et al. Theophylline potential anti-inflammatory effects in nocturnal asthma. J Allergy Clin. Immunol 1996; 97: 1242–46
   PubMed Web of Science ®Google Scholar
• Kyle G M, Smolensky M H, McGovern J P. Circadian variation in the susceptibility of rodents to the toxic effects of theophylline. Chronopharmacology, A Reinberg, F Halberg. Pergamon, OxfordEngland 1979; 239–44
   Google Scholar
• Chronopharmacology. Cellular and biochemical interactions, B Lemmer. Marcel Dekker, New York 1989
   Google Scholar
• Lundback B, Rawlinson D W, Palmer J BD. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993; 48: 148–53
   PubMed Web of Science ®Google Scholar
• Maesen F PV, Smeets J J. Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease. Eur Respir J 1986; 31: 431–36
   Google Scholar
• Maesen F PV, Smeets J J, Gubbelmans H LL, et al. Bronchodilator effect of inhaled formoterol versus salbutamol over 12 hours. Chest 1990a; 97: 590–94
   PubMedGoogle Scholar
• Maesen F PV, Smeets J J, Gubbelmans H LL, et al. Formoterol in the treatment of nocturnal asthma. Chest 1990b; 98: 866–70
   PubMedGoogle Scholar
• Moore-Gillon J. Volmax (salbutamol CR 8 mg) in the management of nocturnal asthma: a placebo-controlled study [abstract]. Eur Respir J 1988; 1(suppl 2)306s
   PubMedGoogle Scholar
• Morrison J FJ, Pearson S B, Dean H G. Parasympathetic nervous system in nocturnal asthma. Br Med J 1988; 296: 1427–29
   PubMed Web of Science ®Google Scholar
• Muir J F, Bertin L, Georges D. Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. Eur Respir J 1992; 5: 1197–1200
   PubMedGoogle Scholar
• Expert Panel report 2, guidelines for the diagnosis and management of asthma. National Institutes of Health, Bethesda, Maryland 1997, National Asthma Education and Prevention Program publication no. 97–4051
   Google Scholar
• National Heart, Lung, and Blood Institute. International consensus report on diagnosis and management of asthma. National Institutes of Health, Bethesda, Maryland 1992, publication no. 92–3091
   Google Scholar
• National Heart, Lung, and Blood Institute and World Health Organization. Global initiative for asthma. National Institutes of Health, Bethesda, Maryland 1995, publication no. 95–3659
   Google Scholar
• Neuenkirchen H, Wikens J H, Oellerich M, et al. Nocturnal asthma: effect of a once per evening dose of sustained-release theophylline. Eur J Respir Dis 1985; 66: 196–204
   PubMedGoogle Scholar
• O'Connor B J, Towse L J, Barnes P J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154(4, pt l)876–80
   PubMedGoogle Scholar
• Pearlman D S, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420–25
   PubMed Web of Science ®Google Scholar
• Pedersen B K, Laursen L C, Gnosspelius Y, et al. Bambuterol: effects of a new antiasthmatic drug. Eur J Clin Pharmacol 1985; 29: 425–27
   PubMed Web of Science ®Google Scholar
• Persson G, Gnosspelius Y, Anehus S. Comparison between a new once-daily, bron-chodilating drug, bambuterol, and terbutaline sustained-release, twice-daily. Eur Respir J 1988; 1: 223–26
   PubMedGoogle Scholar
• Petrie G R, Chookang J Y, Hassan W U, et al. Bambuterol: effective in nocturnal asthma. Respir Med 1993; 87: 581–85
   PubMedGoogle Scholar
• Pierson W E, LaForce C F, Bell T D, et al. Long-term, double blind comparisons of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma. J Allergy Clin Immunol 1990; 85: 618–26
   PubMedGoogle Scholar
• Postma D S, Koeter G H, Keyzer J J. Influence of slow-release terbutaline on the circadian variation of catecholamines, histamine, and lung function in nonallergic patients with partly reversible airflow obstruction. J Allergy Clin Immunol 1986; 77: 471–477
   PubMed Web of Science ®Google Scholar
• Postma D S, Koeter G H, v.d. Mark T W, et al. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest 1985; 87: 653–57
   PubMed Web of Science ®Google Scholar
• Powell M L, Weisberger M, Dowdy Y, et al. Comparative steady-state bioavailability of conventional and controlled-release formulation of albuterol. Biopharm Drug Dispos 1987; 8: 461–67
   PubMedGoogle Scholar
• Physiology and pharmacology of biological rhythms, P Redfern, B Lemmer. Springer-Verlag, Heidelberg 1997
   Google Scholar
• Reinberg A, Pauchet F, Ruff F, et al. Comparison of once-daily evening versus morning sustained-release theophylline dosing for nocturnal asthma. Chronobiol Int 1987; 4: 409–20
   PubMed Web of Science ®Google Scholar
• Schulz H -U, Frercks H -J, Hypa F. Vergleichende Theophyllin-Serum-Spiegel Messungen über 24 stunden nach konventioneller Dosierung ciner Theophyllin-retard-Präparation über 4 Tage. Therapie Woche 1984; 34: 536–43
   Google Scholar
• Selby C, Engleman H M, Fitzpatrick M F, et al. Inhaled salmeterol or oral theophylline in nocturnal asthma. Am J Respir Crit Care Med 1997; 155(1)104–8
   PubMedGoogle Scholar
• Smolensky M H. Chronopharmacology of theophylline and beta-sympafhomimet-ics. Chronopharmacology. Cellular and biochemical interactions, B Lemmer. Marcel Dekker, New York 1989; 65–113
   Google Scholar
• Smolensky M H, McGovern J P, Scott P H, et al. Chronobiology and asthma 11. Body-time-dependent differences in the kinetics and effects of bronchodilator medications. J Asthma 1987; 24: 90–134
   Google Scholar
• Smolensky M H, Scott P H, Harrist R B, et al. Administration-time dependency of the pharmacokinetic behavior and therapeutic effect of a once-a-day theophylline in asthmatic children. Chronobiol Int 1987; 4: 435–48
   PubMed Web of Science ®Google Scholar
• Storms W W, Nathan R A, Bodman S F, et al. The effects of repeat action albuterol sulfate (Proventil Repetabs) in nocturnal symptoms of asthma. J Asthma 1992; 29: 209–16
   PubMed Web of Science ®Google Scholar
• Sullivan P, Songul B, Jaffar Z, et al. Anti-inflammatory effects of low dose oral theophylline in atopic asthma. Lancet 1994; 343: 1006–8
   PubMedGoogle Scholar
• Sykes R S, Reese M E, Meyer M C, et al. Relative bioavailability of a controlled-release albuterol formation for twice-daily use. Biopharm Drug Dispos 1988; 9: 551–56
   PubMedGoogle Scholar
• Torvik J A, Borish L C, Beam W R, et al. Does theophylline alter inflammation in nocturnal asthma? [abstract]. Am J Respir Crit Care Med 1994; 149: A210
   Google Scholar
• Trudeau J B, Martin R J, Kraft M, et al. Theophylline decreases stimulated alveolar macrophage leukotriene B4 (LTB4) production in nocturnal asthmatics lavaged at 4 A.M [abstract]. Am J Respir Crit. Care Med 1994; 149: A941
   Google Scholar
• Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. Am Rev Resp Dis 1990; 142: 571–75
   PubMedGoogle Scholar
• Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled beta2-adrenorceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674–78
   PubMed Web of Science ®Google Scholar
• Van Keimpema A R, Ariaansz M, Raaijmakers J A, et al. Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients. J Asthma 1996; 33: 119–24
   PubMed Web of Science ®Google Scholar
• Ward A JM, McKenniff M, Evans J M, et al. Theophylline: an immunomodulatory role in asthma. Am Rev Respir Dis 1993; 147: 518–23
   PubMed Web of Science ®Google Scholar
• Weersink E J, Dourna R R, Postma D S, et al. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am J Respir Crit Care Med 1997; 155(4)1241–46
   PubMedGoogle Scholar
• Wolstenholme R J, Shettan S R. Comparison of a combination of fenoterol with ipratropium bromide (Duovent) and salbutamol in young adults with nocturnal asthma. Respiration 1989; 55: 152–57
   PubMedGoogle Scholar